Barclays’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-709
| Closed | -$19.1K | – | 5223 |
|
|
2023
Q1 | $19.1K | Sell |
709
-53,139
| -99% | -$2.47M | ﹤0.01% | 4667 |
|
|
2022
Q4 | $1.91M | Buy |
53,848
+36,289
| +207% | +$4.36M | ﹤0.01% | 2288 |
|
|
2022
Q3 | $3.97M | Sell |
17,559
-10
| -0.1% | -$2.46K | ﹤0.01% | 1305 |
|
|
2022
Q2 | $3.32M | Buy |
17,569
+729
| +4% | +$147K | ﹤0.01% | 1545 |
|
|
2022
Q1 | $4.19M | Buy |
16,840
+15,545
| +1,200% | +$2.46M | ﹤0.01% | 1342 |
|
|
2021
Q4 | $202K | Buy |
1,295
+859
| +197% | +$166K | ﹤0.01% | 3563 |
|
|
2021
Q3 | $87K | Buy |
436
+159
| +57% | +$37.8K | ﹤0.01% | 3965 |
|
|
2021
Q2 | $70K | Sell |
277
-609
| -69% | -$152K | ﹤0.01% | 3980 |
|
|
2021
Q1 | $235K | Sell |
886
-1,318
| -60% | -$415K | ﹤0.01% | 3633 |
|
|
2020
Q4 | $814K | Sell |
2,204
-681
| -24% | -$195K | ﹤0.01% | 2906 |
|
|
2020
Q3 | $704K | Buy |
2,885
+1,053
| +57% | +$328K | ﹤0.01% | 2964 |
|
|
2020
Q2 | $527K | Buy |
1,832
+1,236
| +207% | +$364K | ﹤0.01% | 3303 |
|
|
2020
Q1 | $123K | Sell |
596
-245
| -29% | -$78.1K | ﹤0.01% | 4654 |
|
|
2019
Q4 | $375K | Buy |
841
+377
| +81% | +$134K | ﹤0.01% | 4539 |
|
|
2019
Q3 | $142K | Sell |
464
-123
| -21% | -$40K | ﹤0.01% | 5211 |
|
|
2019
Q2 | $187K | Sell |
587
-1,836
| -76% | -$636K | ﹤0.01% | 5174 |
|
|
2019
Q1 | $1.02M | Sell |
2,423
-465
| -16% | -$187K | ﹤0.01% | 3382 |
|
|
2018
Q4 | $881K | Buy |
+2,888
| New | +$933K | ﹤0.01% | 3252 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7463 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7371 |
|
|
2018
Q1 | – | Sell |
-187
| Closed | -$55.2K | – | 7415 |
|
|
2017
Q4 | $78K | Buy |
+187
| New | +$66.8K | ﹤0.01% | 5433 |
|
|
2017
Q3 | – | Sell |
-237
| Closed | -$64.6K | – | 7105 |
|
|
2017
Q2 | $56K | Buy |
237
+216
| +1,029% | +$49.1K | ﹤0.01% | 5287 |
|
|
2017
Q1 | $7K | Buy |
+21
| New | +$7.23K | ﹤0.01% | 6204 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | -$366 | – | 6892 |
|
|
2016
Q3 | $0 | Buy |
+1
| New | +$510 | ﹤0.01% | 6849 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6704 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6508 |
|
|
2015
Q4 | – | Sell |
-25
| Closed | -$14.1K | – | 6713 |
|
|
2015
Q3 | $11K | Buy |
+25
| New | +$13.3K | ﹤0.01% | 5747 |
|
|
2015
Q2 | – | Sell |
-219
| Closed | -$606K | – | 7256 |
|
|
2015
Q1 | $1.77M | Buy |
+219
| New | +$1.91M | ﹤0.01% | 2437 |
|
|
2014
Q4 | – | Sell |
-2
| Closed | -$11.6K | – | 7135 |
|
|
2014
Q3 | $10K | Sell |
2
-15
| -88% | -$79.3K | ﹤0.01% | 6901 |
|
|
2014
Q2 | $121K | Buy |
+17
| New | +$85.1K | ﹤0.01% | 5274 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 7414 |
|
Other funds holding EIGR
6CM
SAM
UOC
RC
GCP
Barclays's EIGR Position: Q2 2023 in Review
Barclays sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 709 shares — an estimated $19.1K sold.
Barclays first reported a position in EIGR in Q2 2014 and held it in 26 quarters. The position peaked at $4.19M in Q1 2022. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.
- Barclays reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Barclays sold 709 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $19.1K.
- Barclays first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 26 quarters.
- Barclays's Eiger BioPharmaceuticals, Inc. position peaked at $4.19M in Q1 2022.
- 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.